At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
01801 INNOVENT BIO
Closed 09-16 16:08:46
94.100
-0.900
-0.95%
High95.450Low93.850Vol6.23M
Open95.000D1 Closing95.000Amplitude1.68%
Mkt Cap164.20BTradable Cap164.20BTotal Shares1.75B
T/O587.86MT/O Rate0.36%Tradable Shares1.75B
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.
Big Pharma is Pouring Billions into China's Biotechs
Dow Jones  ·  09-14 15:59
Big Pharma is Pouring Billions into China's Biotechs
Innovent's Enlarged Cash Holdings, Investment Fair Value Could Boost Earnings
Dow Jones  ·  09-14 15:40
Innovent's Enlarged Cash Holdings, Investment Fair Value Could Boost Earnings
Movement Alert｜INNOVENT BIO Rises 3.21% in Regular Trading, WCLC Data Releases Catalyze Broad Innovative Drug Sector Rally
Market Focus  ·  09-14 14:31
Movement Alert｜INNOVENT BIO Rises 3.21% in Regular Trading, WCLC Data Releases Catalyze Broad Innovative Drug Sector Rally
HK Stocks in Focus: Innovative Drug Sector Surges on WCLC Data Boost, Analysts See Value After Pullback
Stock News  ·  09-14 14:00
HK Stocks in Focus: Innovative Drug Sector Surges on WCLC Data Boost, Analysts See Value After Pullback
HK Stock Market Update | Innovative Drug Stocks Face Continued Pullback Amid Shifting Overseas Rate Expectations and Post-2026 Negotiation Uncertainty
Stock News  ·  09-11
HK Stock Market Update | Innovative Drug Stocks Face Continued Pullback Amid Shifting Overseas Rate Expectations and Post-2026 Negotiation Uncertainty
Movement Alert｜INNOVENT BIO Drops 3.11% in Regular Trading, Southbound Funds Continue Selling Amid Biotech Sector Weakness and Insurance Negotiation Uncertainty
Market Focus  ·  09-10
Movement Alert｜INNOVENT BIO Drops 3.11% in Regular Trading, Southbound Funds Continue Selling Amid Biotech Sector Weakness and Insurance Negotiation Uncertainty
Movement Alert｜INNOVENT BIO Falls 3.01% in Regular Trading, Biotech Sector Under Pressure Amid NRDL Negotiation Uncertainty
Market Focus  ·  09-08
Movement Alert｜INNOVENT BIO Falls 3.01% in Regular Trading, Biotech Sector Under Pressure Amid NRDL Negotiation Uncertainty
UBS Flags Strong H1 Sales for Chinese Biotech Despite Regulatory Headwinds, Eyes Late-Year Catalysts
Stock News  ·  09-07
UBS Flags Strong H1 Sales for Chinese Biotech Despite Regulatory Headwinds, Eyes Late-Year Catalysts
Brokerage Adds Tencent and Innovent Bio to Buy List While Maintaining Positive Outlook on Tech and Hardware Sectors
Stock News  ·  09-04
Brokerage Adds Tencent and Innovent Bio to Buy List While Maintaining Positive Outlook on Tech and Hardware Sectors
Innovent Biologics Grants 59,757 Options and 583,731 Restricted Shares Under 2024 Incentive Scheme
Bulletin Express  ·  09-01
Innovent Biologics Grants 59,757 Options and 583,731 Restricted Shares Under 2024 Incentive Scheme
Innovent Biologics Grants 583,731 Restricted Shares Under 2024 Share Scheme
Reuters  ·  09-01
Innovent Biologics Grants 583,731 Restricted Shares Under 2024 Share Scheme
Innovent Biologics Files List of Board, Board Committee Members with Disclosure Duties
Reuters  ·  09-01
Innovent Biologics Files List of Board, Board Committee Members with Disclosure Duties
Movement Alert｜INNOVENT BIO Falls 3.16% in Regular Trading, Post-Earnings Profit-Taking Continues as Biotech Sector Sells Off Broadly
Market Focus  ·  08-31
Movement Alert｜INNOVENT BIO Falls 3.16% in Regular Trading, Post-Earnings Profit-Taking Continues as Biotech Sector Sells Off Broadly
China's Dawnrays Pharmaceutical H1 Revenue Falls on Lower Procurement Prices
Reuters  ·  08-28
China's Dawnrays Pharmaceutical H1 Revenue Falls on Lower Procurement Prices
Earnings Beat: Innovent Biologics, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
Simply Wall St.  ·  08-28
Earnings Beat: Innovent Biologics, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
Innovent Biologics Files HKEX Next-Day Disclosure Return, Issues 182,021 New Shares
Reuters  ·  08-27
Innovent Biologics Files HKEX Next-Day Disclosure Return, Issues 182,021 New Shares
Nomura Adjusts Innovent Biologics' Price Target to HK$125 From HK$105, Keeps at Buy
MT Newswires Live  ·  08-27
Nomura Adjusts Innovent Biologics' Price Target to HK$125 From HK$105, Keeps at Buy
China's CStone Pharmaceuticals H1 Revenue Soars on Drug Sales
Reuters  ·  08-27
China's CStone Pharmaceuticals H1 Revenue Soars on Drug Sales
China's JW Therapeutics Interim Revenue Rises 4.7% on Carteyva Sales
Reuters  ·  08-27
China's JW Therapeutics Interim Revenue Rises 4.7% on Carteyva Sales
Biocytogen Pharmaceuticals H1 Revenue up 51.6%
Reuters  ·  08-27
Biocytogen Pharmaceuticals H1 Revenue up 51.6%

Introduction

Company Name.
INNOVENT BIO
Affiliated Markets:
SEHK
Listing Date:
--
Main Business:
Innovent Biologics Inc is an investment holding company principally engaged in the research, development, production and sales of innovative medicines for the treatment of diseases such as cancer, cardiovascular and metabolic (CVM), autoimmune and eye diseases. The pipeline covering monoclonal antibodies, multi-specific antibodies, immuno-cytokine, antibody-drug conjugates (ADCs), cell therapy and small molecules. The Company’s main products include TYVYT (sintilimab injection), BYVASDA (bevacizumab injection), SULINNO (adalimumab injection), HALPRYZA (rituximab injection), Pemazyre (pemigatinib) and others. The Company mainly conducts its businesses within domestic and overseas markets.
Issue price:
--